PD-L1 Negative: Is It Good or Bad for Your Cancer Treatment?

A PD-L1 negative result means your tumor shows little or no detectable PD-L1 protein, a molecule cancer cells sometimes display on their surface. For treatment decisions, that result is neither straightforwardly good nor bad. It does make you less likely to respond to immunotherapy drugs used alone, but it does not shut the door on immunotherapy entirely, and it certainly does not define your overall prognosis. The reality is more layered than any single biomarker can capture, and the test itself has real limitations that can change the picture.

What a PD-L1 Test Actually Measures

PD-L1 is a protein that sits on the surface of some tumor cells and some immune cells within the tumor. When it’s present, it can bind to a receptor on T cells called PD-1, essentially telling those immune cells to stand down. Immunotherapy drugs called checkpoint inhibitors block that handshake, freeing the immune system to attack the cancer. The PD-L1 test tries to gauge how much of that protein your tumor expresses, which in theory should predict how well those drugs will work.

There are two main scoring systems. The Tumor Proportion Score (TPS) counts only the percentage of tumor cells that stain positive for PD-L1. The Combined Positive Score (CPS) is broader: it counts PD-L1-positive tumor cells plus PD-L1-positive immune cells in the tumor area, divided by total tumor cells, then multiplied by 100.¹ Different cancer types use different scoring systems and different cutoffs. In lung cancer, a TPS below 1% is generally considered PD-L1 negative. In gastric cancer and triple-negative breast cancer, CPS is more commonly used, and a CPS below 1 is typically the negative threshold.² Which scoring system matters for you depends entirely on what kind of cancer you have and which treatment your oncologist is considering.

How Well Immunotherapy Works When PD-L1 Is Negative

The honest answer is: less well than in PD-L1-positive patients, but not zero. A large pooled analysis across multiple cancer types found that about 10% of PD-L1-negative patients responded to checkpoint inhibitor monotherapy, compared with roughly 24% of PD-L1-positive patients.³ That gap is real. But the same analysis found something encouraging: even in PD-L1-negative patients, immunotherapy monotherapy still reduced the risk of death compared with conventional treatment. The survival benefit was smaller than in PD-L1-positive patients, but it was there.³

Where things change dramatically is when immunotherapy is combined with chemotherapy. In PD-L1-negative non-small cell lung cancer (NSCLC), a meta-analysis of twelve trials found that adding a checkpoint inhibitor to chemotherapy improved response rates, slowed disease progression, and extended survival compared to chemotherapy alone.⁴ Another analysis focused specifically on PD-L1-negative NSCLC found that immunotherapy combined with chemotherapy achieved response rates around 48%, compared with just 11% for immunotherapy alone. Median overall survival jumped from about 10 months with solo immunotherapy to roughly 15 to 16 months with the combination.⁵ The chemotherapy appears to prime the immune system by killing tumor cells and releasing their contents, making the remaining cancer more visible to immune attack even when PD-L1 levels are low.

PD-L1 Is a Weaker Predictor Than Many People Assume

If you’ve been told your tumor is PD-L1 negative, it’s worth knowing that PD-L1 status is not the reliable gatekeeper it’s sometimes made out to be. A review of all FDA approvals for immune checkpoint inhibitors found that PD-L1 was predictive of response in fewer than 30% of those approvals. In the majority, PD-L1 was either not predictive or was never even tested as part of the approval process.⁶ In other words, for many cancer types and many approved immunotherapy drugs, PD-L1 status was not the deciding factor in whether the drug worked.

This is partly why several immunotherapy drugs are approved without any PD-L1 testing requirement. In bladder cancer, for example, second-line checkpoint inhibitors are approved regardless of PD-L1 status. The testing requirement applies only in certain first-line situations for patients who can’t tolerate platinum-based chemotherapy.⁷ For lung cancer, guidelines have long recommended checkpoint inhibitors as preferred second-line agents for metastatic disease across both squamous and nonsquamous types, based on better survival and fewer side effects than older chemotherapy.⁸ The takeaway: a PD-L1 negative result narrows your options for immunotherapy monotherapy as a first-line treatment in some cancers, but it rarely eliminates immunotherapy from the conversation entirely.

The Test Itself Can Be Wrong

One of the most important things to understand about a PD-L1 negative result is that the test has genuine accuracy problems. PD-L1 expression isn’t uniform across a tumor. One section of the tumor might express it while another section doesn’t. When only a small biopsy sample is taken, the test may miss the positive areas entirely. In lung adenocarcinoma, a study of multi-core biopsies found that about 14% of samples were positive in only one core out of several, meaning a single-core biopsy would have returned a false negative result.⁹

The problem goes beyond tumor heterogeneity. The size of the sample matters too. In triple-negative breast cancer, comparing small diagnostic biopsies to larger surgical specimens revealed that roughly 22% more tumors were classified as PD-L1-positive when the larger specimen was examined. The researchers concluded that a meaningful subset of patients may be misclassified as PD-L1 negative and wrongly excluded from immunotherapy.¹⁰ A similar pattern showed up in gastric cancer, where false negatives (a negative biopsy from a patient whose surgically removed tumor turned out to be positive) occurred in about 30% of cases.¹¹

On top of sample-size issues, the staining kits used to detect PD-L1 don’t always agree with each other. Different antibody assays (22C3, 28-8, and SP142 are the most common) sometimes give conflicting results on the same tumor. In one study, 40% of tumor cases showed a different PD-L1 classification depending on which assay was used.¹² Another study found only moderate agreement across assays when using the clinical cutoffs tied to specific drugs, with particularly poor concordance for immune cell scoring.¹³ So a patient tested with one assay might be called PD-L1 negative while the same tumor tested with a different assay might come back positive.

Other Biomarkers That Matter When PD-L1 Is Negative

Because PD-L1 is an imperfect predictor, oncologists increasingly look at additional biomarkers. Two of the most important are tumor mutational burden (TMB) and microsatellite instability (MSI).

TMB measures how many mutations exist in a tumor’s DNA. The logic is simple: more mutations generally mean more abnormal proteins for the immune system to recognize, regardless of PD-L1 status. A study in NSCLC found that high TMB was independently associated with better response rates, longer progression-free survival, and longer overall survival after checkpoint inhibitor treatment, and this held true across PD-L1 expression levels.¹⁴ That means a PD-L1-negative patient with a high TMB may still respond well to immunotherapy.

MSI is another marker, most commonly relevant in colorectal, endometrial, and gastric cancers. Tumors with high microsatellite instability (MSI-H) tend to accumulate many mutations and are often sensitive to checkpoint inhibitors. Here’s the twist: the overlap between these markers is surprisingly small. In a large analysis of over 11,000 patients, only about a quarter of MSI-H tumors were also PD-L1 positive, and only 0.6% of all tumors tested were positive for all three markers (TMB-high, MSI-H, and PD-L1 positive).¹⁵ Each marker captures a different slice of immune responsiveness. Knowing your TMB or MSI status can completely change what a PD-L1-negative result means for your treatment options.

Radiation Can Flip PD-L1 From Negative to Positive

PD-L1 expression is not a fixed property of your cancer. It can change over time and in response to treatment, particularly radiation therapy. Radiation damages tumor DNA and triggers inflammatory signals that can upregulate PD-L1 on both tumor cells and the immune cells within the tumor’s environment.¹⁶

This has been seen in real patients. In a study of soft tissue sarcoma, about 11% of patients showed elevated PD-L1 on tumor cells after radiation, and the increase on tumor-associated immune cells was even more striking, rising from about 15% of patients before radiation to nearly 46% after.¹⁷ Laboratory studies in bladder cancer cells confirmed a similar dose-dependent pattern: higher radiation doses led to greater PD-L1 expression, with the increase peaking around 48 hours after treatment.¹⁸

This creates both a challenge and an opportunity. On one hand, a PD-L1 test taken before radiation might not reflect what the tumor looks like afterward. On the other hand, the radiation-induced increase in PD-L1 has sparked interest in combining radiation with immunotherapy, since the radiation may create a window where the tumor becomes vulnerable to checkpoint inhibitors even if it wasn’t initially. Several clinical trials are exploring this sequencing strategy, though it hasn’t yet become standard practice.

What PD-L1 Negative Looks Like in Specific Cancers

The practical meaning of a PD-L1 negative result varies significantly by cancer type. In NSCLC, the most common context for PD-L1 testing, PD-L1-negative patients are typically treated with immunotherapy plus chemotherapy rather than immunotherapy alone. Multiple analyses confirm this combination outperforms either treatment by itself.⁵ Researchers are also studying whether dual immunotherapy (two different checkpoint inhibitors together) might outperform the immunotherapy-chemotherapy combination in PD-L1-negative lung cancer. So far, the evidence doesn’t show a clear advantage for that approach, and the standard chemotherapy-plus-immunotherapy pairing tends to cause fewer treatment-ending side effects.¹⁹²⁰

In gastric cancer, PD-L1 testing usually relies on the CPS rather than TPS. A meta-analysis found that patients with CPS of 1 or higher benefited from immunotherapy combined with other treatments, with improved survival and slower disease progression. For those below that threshold, the benefits were less consistent, though single-agent immunotherapy still offered some survival improvement in the CPS-positive subgroup.²¹

In triple-negative breast cancer (TNBC), PD-L1 negativity has historically meant exclusion from immunotherapy options like pembrolizumab combined with chemotherapy. For PD-L1-negative metastatic TNBC, standard first-line treatment still relies on chemotherapy, most commonly cyclophosphamide-and-doxorubicin-based regimens or single-agent options like capecitabine or paclitaxel. Median overall survival in this population is roughly 12 months, and treatment sequences are highly variable.²² That said, the previously discussed biopsy accuracy problems are particularly relevant here, since the false-negative rate in TNBC is concerning enough that some researchers argue retesting should be considered.

The Tumor Microenvironment Tells a Fuller Story

PD-L1 is just one piece of the immune landscape inside your tumor. Tumor-infiltrating lymphocytes, or TILs, are immune cells that have already migrated into the tumor tissue. Their presence generally signals that the immune system is already trying to fight the cancer. In triple-negative breast cancer, patients with high TIL levels had better overall survival than those with low levels.²³ Interestingly, the interaction between TILs and PD-L1 mattered more than either alone. The worst prognosis was seen in patients whose tumors were PD-L1 positive but had few TILs, suggesting the tumor was using PD-L1 to suppress the few immune cells attempting to infiltrate.²³

For a PD-L1-negative patient, this context matters. A PD-L1-negative tumor with abundant TILs might still respond to immunotherapy, because the immune system is already engaged. A PD-L1-negative tumor with few TILs is a colder immune environment and likely needs a different approach to wake up the immune response. Research in this area is active, with genomic studies trying to identify the specific alterations that drive immune exclusion in tumors that appear “cold” by all standard markers.²⁴

Liquid Biopsies and the Future of PD-L1 Testing

Given the well-documented problems with tissue-based PD-L1 testing, researchers are developing blood-based alternatives called liquid biopsies. These tests analyze circulating tumor cells, fragments of tumor DNA, or tiny vesicles shed by tumors into the bloodstream. The idea is appealing: a blood draw is far less invasive than a tissue biopsy, it can be repeated easily to track changes over time, and it samples the tumor’s biology more broadly than a single needle stick into one part of the mass.²⁵

Early results are intriguing but highlight the complexity. One study measured PD-L1 in cell-free RNA from blood plasma and found that patients who were PD-L1 positive by the blood test had similar overall survival to those who were PD-L1 positive on tissue testing, with identical median survival of about 15 months. Some of those plasma-positive patients had actually tested negative on their tissue biopsy, suggesting the blood test caught something the tissue test missed.²⁶ Separately, research on circulating tumor cells has shown that finding PD-L1-positive tumor cells in the blood after treatment started was associated with worse outcomes, suggesting the blood test might also serve as an early warning system for treatment failure.²⁷ These approaches are still mostly in the research phase, but they may eventually help reclassify some patients who are currently labeled PD-L1 negative based on a single tissue sample.

New Drug Classes for PD-L1-Negative Tumors

Beyond immunotherapy, a class of drugs called antibody-drug conjugates (ADCs) is generating attention for PD-L1-negative cancers, particularly in triple-negative breast cancer. ADCs work differently from checkpoint inhibitors. They are engineered antibodies that carry a chemotherapy payload directly to cancer cells, acting like guided missiles rather than relying on the patient’s immune system. Some researchers believe ADCs might also help prime the immune environment, potentially making tumors more responsive to immunotherapy even when PD-L1 is absent. Clinical trials are underway combining ADCs with checkpoint inhibitors in PD-L1-negative disease to test this hypothesis.²⁸ If these trials succeed, they could open a new treatment pathway for patients currently locked out of immunotherapy-based regimens.

What to Ask Your Oncologist

Patients often have trouble retaining information about biomarker testing, especially when it comes early in their cancer journey alongside a flood of other medical details. Research into patient-clinician communication around biomarker results found that while patients were generally aware that biomarkers influence treatment options, many did not actually know their own test results or understand the expected delays between testing and receiving those results.²⁹ If you’ve been told your tumor is PD-L1 negative, it’s reasonable to ask a few specific questions: which assay was used, what scoring system was applied, whether retesting from a different sample might be appropriate, and whether your tumor has been tested for TMB or MSI as well. These are not adversarial questions. They’re the kind of information that helps you participate meaningfully in treatment planning.

Cost is another factor worth discussing openly. Checkpoint inhibitor therapy carries significantly higher costs than conventional chemotherapy. One study of NSCLC patients in the U.S. found that those receiving checkpoint inhibitors had total semiannual costs nearly double those of patients receiving other treatments.³⁰ For a PD-L1-negative patient weighing whether combination immunotherapy-chemotherapy is worth pursuing versus chemotherapy alone, the financial dimension is part of the conversation, alongside the expected survival benefit and side-effect profile. No biomarker result exists in a vacuum. It’s a data point, not a verdict.